Agomab Therapeutics NV

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing novel disease-modifying therapies for immunology and inflammatory diseases, with a primary focus on chronic fibrotic indications that have high unmet medical needs. The company targets key pathways like the transforming growth factor β (TGFβ) to resolve fibrosis and restore organ function, utilizing small molecules and antibodies designed for enhanced efficacy and reduced systemic toxicities. Its lead pipeline includes Ontunisertib (AGMB-129), an oral small molecule inhibitor of ALK5/TGFβR1 in Phase 2a trials for fibrostenosing Crohn’s disease; AGMB-447, an inhaled inhibitor in Phase 1 for idiopathic pulmonary fibrosis; and AGMB-101, a preclinical HGF-mimetic monoclonal antibody showing antifibrotic and regenerative potential via MET receptor agonism. AgomAb Therapeutics NV retains worldwide rights to its programs, addressing large markets in gastrointestinal, pulmonary, and other fibrotic disorders. Founded in 2017 and headquartered in Antwerp, Belgium, the company employs 58 people led by CEO Tim Knotnerus. It plays a significant role in the biotechnology sector by advancing targeted therapies against fibrotic diseases, supported by recent capital raises to fuel clinical progression.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Tim Knotnerus MSc, Ph.D.

Employees

62

Headquarters

Antwerp, Belgium

Website

www.agomab.com